Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.

abstract：:The aim of this research was to determine the serum dipeptidyl peptidase IV (DPPIV) activity as well as the percentages of CD26 + lymphocytes and CD26 + overall white blood cells in patients with hematological malignancies: non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia, plasmacytoma and multiple myeloma,...

journal_title：Leukemia & lymphoma

authors： Matić IZ,Đorđević M,Đorđić M,Grozdanić N,Damjanović A,Kolundžija B,Vidović A,Bila J,Ristić S,Mihaljević B,Tomin D,Milanović N,Ristić D,Purić M,Gavrilović D,Cordero OJ,Juranić ZD

更新日期：2013-12-01 00:00:00

abstract：:The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...

journal_title：Leukemia & lymphoma

authors： Efremov DG,Ivanovski M,Burrone OR

更新日期：1998-01-01 00:00:00

abstract：:It is unknown whether rituximab increases the risk of second primary malignancies (SPMs) in patients with diffuse large cell B-cell lymphoma (DLBCL). We assessed SPMs in DLBCL patients diagnosed between 1996 and 2014 in comparison with the general Israeli population and dependent on rituximab treatment. Jewish patient...

journal_title：Leukemia & lymphoma

authors： Neeman Y,Perry C,Silverman B,Waintraub N,Avivi I

更新日期：2020-11-01 00:00:00

abstract：:Management of relapsed lymphoma depends upon the variables of chemosensitive disease and successful stem cell mobilization. The microtubule specific agents, paclitaxel and vinorelbine, have efficacy in relapsed lymphoma and can enhance stem cell mobilization. We performed a phase I dose-escalation study of cytarabine ...

journal_title：Leukemia & lymphoma

authors： Lonial S,Arellano M,Hutcherson D,Langston A,Flowers C,Heffner LT,Winton E,Jo Lechowicz M,Waller EK

更新日期：2006-10-01 00:00:00

abstract：:Peripheral blood progenitor cells are being used increasingly as part of the treatment protocol for a variety of haematological malignancies. The most appropriate mobilisation therapy and the optimum collection procedures have yet to be fully elucidated. 28 patients with myeloma (9), NHL (11) and HD (8) underwent PBSC...

journal_title：Leukemia & lymphoma

authors： Scott MA,Ager S,Apperley JF,Jestice HK,Bloxham DM,Boraks P,Mahendra P,Marcus RE

更新日期：1995-11-01 00:00:00

abstract：:In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF)...

journal_title：Leukemia & lymphoma

authors： Fox ML,García-Cadenas I,Pérez AM,Villacampa G,Piñana JL,Ortí G,Montoro J,Roldán E,Bosch Vilaseca A,Martino R,Salamero O,Saavedra S,Hernandez-Boluda JC,Esquirol A,Sierra J,Sanz J,Solano C,Bosch F,Barba P,Valcarcel D

更新日期：2020-08-01 00:00:00

abstract：:Clinical observation and laboratory evidence suggest that immune mechanisms play an important role in the natural control of evolution of the Ph+ clone in chronic phase as well as during progression of chronic myelogenous leukemia (CML). The understanding of these mechanisms could facilitate development of innovative ...

journal_title：Leukemia & lymphoma

authors： Selleri C,Maciejewski JP

更新日期：2000-04-01 00:00:00

abstract：:Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...

journal_title：Leukemia & lymphoma

authors： Finnes HD,Chaffee KG,Call TG,Ding W,Kenderian SS,Bowen DA,Conte M,McCullough KB,Merten JA,Bartoo GT,Smith MD,Leis J,Chanan-Khan A,Schwager SM,Slager SL,Kay NE,Shanafelt TD,Parikh SA

更新日期：2017-06-01 00:00:00

abstract：:Gene array studies on follicular lymphoma (FL) have associated non-malignant tumor-infiltrating immune cells with patient survival. We examined the role of such cells detectable by immunohistochemistry in a tissue microarray, focusing on plasmacytoid dendritic cells (pDCs). These cells physiologically produce interfer...

journal_title：Leukemia & lymphoma

authors： Butsch R,Lukas Waelti S,Schaerer S,Braun J,Korol D,Probst-Hensch N,Moch H,Kurrer M

更新日期：2011-07-01 00:00:00

abstract：:We report the clinical features and outcome of 22 TLS-ERG+ leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with...

journal_title：Leukemia & lymphoma

authors： Pan J,Zhang Y,Zhao YL,Yang JF,Zhang JP,Liu HX,Wu T,Tong CR

更新日期：2017-07-01 00:00:00

abstract：:Multiple myeloma is a B-cell malignancy with a highly variable outcome. Despite the marked recent improvements in its management, especially due to the widespread application of high-dose treatment and autologous stem cell transplantation, relapses eventually occur in the majority of patients. Systematic research at U...

journal_title：Leukemia & lymphoma

authors： Fassas AB,Van Rhee F,Tricot G

更新日期：2003-05-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a myeloproliferative disease well treated by tyrosine kinase inhibitors (TKIs). The aim was to identify genes with a predictive value for relapse-free survival after TKI cessation in CML patients. We performed whole-exome sequencing of DNA from six CML patients in long-lasting deep mo...

journal_title：Leukemia & lymphoma

authors： Smirnikhina SA,Lavrov AV,Chelysheva EY,Adilgereeva EP,Shukhov OA,Turkina A,Kutsev SI

更新日期：2016-07-01 00:00:00

abstract：:Patients with localized follicular lymphoma are potentially curable; however, the failure rate for local treatment suggests that a proportion of apparently localized disease is being under-staged. We report a case of incidentally diagnosed follicular lymphoma found in association with a stage II malignant melanoma, wi...

journal_title：Leukemia & lymphoma

authors： Dickinson M,Wotherspoon A,Cunningham D

更新日期：2006-03-01 00:00:00

abstract：:Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients...

journal_title：Leukemia & lymphoma

authors： Kouroukis CT,Fernandez LA,Crump M,Gascoyne RD,Chua NS,Buckstein R,Turner R,Assouline S,Klasa RJ,Walsh W,Powers J,Eisenhauer E

更新日期：2011-03-01 00:00:00

abstract：:With improving lymphoma survival, late effects of therapy have emerged. Here, we describe pattern of long-term chronic kidney disease (CKD) in lymphoma survivors. Demographics, comorbidities, lymphoma histology, treatment, and outcome were recorded. Glomerular filtration rate (GFR) was recorded at diagnosis, 1, 2, 5, ...

journal_title：Leukemia & lymphoma

authors： Desai SH,Al-Shbool G,Desale S,Veis J,Malkovska V

更新日期：2020-12-01 00:00:00

abstract：:Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...

journal_title：Leukemia & lymphoma

authors： Higuchi T,Oba R,Endo M,Harada H,Mori H,Niikura H,Omine M,Fujita K

更新日期：1999-03-01 00:00:00

abstract：:The aim of this study was to assess life goal achievements in long-term survivors (LTS) receiving cranial radiotherapy (CRT) as central nervous system (CNS) prophylaxis for acute lymphoblastic leukemia (ALL) during childhood, compared to healthy individuals. Participants in this study were 141 LTS treated in our cente...

journal_title：Leukemia & lymphoma

authors： Pillon M,Tridello G,Boaro MP,Messina C,Putti MC,Varotto S,Petris MG,Scrimin S,Zanesco L,Rosolen A,Basso G

更新日期：2013-02-01 00:00:00

abstract：:A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regime...

journal_title：Leukemia & lymphoma

authors： Tsutsumi Y,Kawamura T,Saitoh S,Yamada M,Obara S,Miura T,Kanamori H,Tanaka J,Asaka M,Imamura M,Masauzi N

更新日期：2004-03-01 00:00:00

abstract：:The outcome of sixty-four patients with acute leukemia in first remission who had been treated with either bone marrow transplantation (BMT) or conventional chemotherapy was retrospectively evaluated (a median follow-up of 37 months). Among them, 26 patients (age range; 14-42 years) received allogeneic BMT from HLA-id...

journal_title：Leukemia & lymphoma

authors： Tamura S,Takemoto Y,Kanamaru A,Fujiwara H,Miyazaki E,Fujimori Y,Inoue N,Okamoto T,Kohsaki M,Kakishita E

更新日期：1992-11-01 00:00:00

abstract：:Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature. This malignancy is difficult to diagnose because of its rarity, and because of the subtle histopathologic features that distinguish IDCS from similar tumors arising from reti...

journal_title：Leukemia & lymphoma

authors： Olnes MJ,Nicol T,Duncan M,Bohlman M,Erlich R

更新日期：2002-04-01 00:00:00

abstract：:Rapamycin and its derivatives have been proposed in the treatment of leukemia based on their cytostatic effects, but their possible role in differentiation therapy is less explored. The aim of the present study was to investigate the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide (D...

journal_title：Leukemia & lymphoma

authors： Lalic H,Lukinovic-Skudar V,Banfic H,Visnjic D

更新日期：2012-11-01 00:00:00

abstract：:Immunophenotypic analysis was performed in 53 cases of B chronic lymphocytic leukemia using a large panel of monoclonal antibodies recognizing B, T, activation and myeloid antigens. Our results showed four patterns of reactivity: (a) several molecules were constantly expressed: CD19, CD20, CD24, CD37, HLA-DR, mu heavy...

journal_title：Leukemia & lymphoma

authors： Legac E,Chastang C,Binet JL,Michel A,Debre P,Merle-Beral H

更新日期：1991-01-01 00:00:00

abstract：:In myelodysplastic syndrome (MDS), vascular endothelial growth factor (VEGF) may have regulatory effects on the hematopoietic system and contribute to disease progression. We analyzed by immunocytochemistry VEGF expression in bone marrow (BM) cells from 188 patients with MDS and 96 non-hemopathic subjects. We also mea...

journal_title：Leukemia & lymphoma

authors： Invernizzi R,Travaglino E,Della Porta MG,Malcovati L,Gallì A,Bastia R,Ciola M,Ambaglio I,Boveri E,Rosti V,Cazzola M

更新日期：2017-07-01 00:00:00

abstract：:The objective of this article was to investigate the relationship between IRF-3 gene polymorphisms and the susceptibility and prognosis of CLL. Between January 2011 and August 2012, 108 CLL patients and 112 healthy were enrolled in the study. DHPLC and Shesis software were applied in our study. In rs7251, CG genotype ...

journal_title：Leukemia & lymphoma

authors： Zhang ZX,Shen CF,Shou LH,Fang Q

更新日期：2017-03-01 00:00:00

abstract：:Deletions involving chromosome 6q have been reported in a number of human cancers such as ovarian and breast tumours as well as haematopoietic malignancies. It seems that this region might contain tumour-suppressor genes. Putative natural killer cell lymphomas/leukaemias (NKLL) represent a group of recently characteri...

journal_title：Leukemia & lymphoma

authors： Ohshima K,Haraokaa S,Ishihara S,Ohgami A,Yoshioka S,Suzumiya J,Kikuchi M

更新日期：2002-02-01 00:00:00

abstract：:Granulocytic sarcoma (chloroma) is a rare solid tumor resulting from the proliferation of myelogenous leukemia cells. Chloromas usually present as soft tissue or bony masses of the head and neck in patients with acute myelogenous leukemia (AML) of the French-American-British M2 subtype. Occasionally chloromas may occu...

journal_title：Leukemia & lymphoma

authors： Landis DM,Aboulafia DM

更新日期：2003-10-01 00:00:00

abstract：:Abstract Reconstitution, engraftment kinetics and tumor cell clearance were analyzed after reduced intensity conditioning hematopoietic cell transplant (RIC-HCT) in patients with chronic lymphocytic leukemia (CLL). Patients were transplanted from unrelated (n = 40) or related (n = 10) donors after fludarabine and 2 Gy...

journal_title：Leukemia & lymphoma

authors： Hebenstreit K,Iacobelli S,Leiblein S,Eisfeld AK,Pfrepper C,Heyn S,Vucinic V,Franke GN,Krahl R,Fricke S,Becker C,Pönisch W,Behre G,Niederwieser D,Lange T

更新日期：2014-06-01 00:00:00

abstract：:Twenty-six non-Hodgkin's malignant lymphomas (ML) of the Waldeyer's ring, the mouth and nasal cavities were studied morphologically and immunohistochemically on paraffin and frozen sections. A B-cell origin was shown in all 14 cases of Waldeyer's ring M.L., while 5 of 7 nasal and 3 of 5 buccal cases were of T-cell nat...

journal_title：Leukemia & lymphoma

authors： Papadimitriou CS,Bai MK

更新日期：1991-01-01 00:00:00

abstract：:Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...

journal_title：Leukemia & lymphoma

authors： Wang TF,Ahluwalia R,Fiala MA,Trinkaus KM,Cox DP,Jaenicke M,Moliske CC,Carson KR,Wildes TM,Tomasson MH,Stockerl-Goldstein KE,Vij R

更新日期：2014-02-01 00:00:00

abstract：:Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing ...

journal_title：Leukemia & lymphoma

authors： Pozzi S,Gentile M,Sacchi S,Marcheselli R,Corso A,Cocito F,Musto P,Guarini A,Minoia C,Vincelli I,Ria R,Rivolti E,Mele G,Bari A,Mazzone C,Badiali S,Marcheselli L,Palumbo A,Morabito F

更新日期：2017-03-01 00:00:00